Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma
- PMID: 25501064
- PMCID: PMC4602816
- DOI: 10.1097/MD.0000000000000183
Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma
Abstract
Malignancies are one of the main causes of mortality in diabetic patients; however, to date, very limited data have been reported on the specific influence of type 2 diabetes mellitus (T2DM) on the survival of patients with renal cell carcinoma (RCC). In the present long-term retrospective study, we investigated whether T2DM may influence the overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS) in patients with surgically treated RCC. Medical records of 924 patients treated by radical or partial nephrectomy for sporadic, unilateral RCC were reviewed. Patients with type-1 DM and with T2 DM receiving insulin treatment were excluded. Survival estimates were calculated according to the Kaplan-Meier method and compared with the log-rank test. Univariate and multivariate analyses were performed using the Cox regression model.Of the 924 RCC patients, 152 (16.5%) had T2DM. Mean follow-up was 68.5 months. Mean OS was 41.3 and 96.3 months in T2DM and non-T2DM patients, respectively (P < 0.0001).The estimated CSS rates at 1, 3, and 5 years in T2DM versus non-T2DM patients were 63.4% versus 76.7%, 30.4% versus 56.6%, and 16.3% versus 48.6%, respectively (P = 0.001). Mean PFS was significantly lower (31.5 vs 96.3 months; P < 0.0001) in the T2DM group. At multivariate analysis, T2DM was an independent adverse prognostic factor for OS (hazard ratio [HR] = 3.44; 95% confidence interval [CI]:2.40-4.92), CSS (HR = 6.39; 95% CI: 3.78-10.79), and PFS (HR = 4.71; 95% CI: 3.11-7.15). In conclusion, our findings suggest that patients with RCC and pre-existing T2DM have a shorter OS, increased risk of recurrence, and higher risk for kidney cancer mortality than those without diabetes.
Figures





Similar articles
-
Pre-existing type 2 diabetes is an adverse prognostic factor in patients with renal cell carcinoma.J Diabetes. 2019 Dec;11(12):993-1001. doi: 10.1111/1753-0407.12957. Epub 2019 Jun 26. J Diabetes. 2019. PMID: 31141620 Free PMC article.
-
Pre-existing type-2 diabetes is not an adverse prognostic factor in patients with renal cell carcinoma: a single-center retrospective study.Urol Oncol. 2013 Oct;31(7):1310-5. doi: 10.1016/j.urolonc.2011.12.013. Epub 2012 Jan 24. Urol Oncol. 2013. PMID: 22281433
-
Prognostic Significance of Blood Type A in Patients with Renal Cell Carcinoma.Urol J. 2016 Aug 25;13(4):2765-72. Urol J. 2016. PMID: 27576883
-
The Impact of Diabetes Mellitus on Renal Cell Carcinoma Prognosis: A Meta-Analysis of Cohort Studies.Medicine (Baltimore). 2015 Jul;94(26):e1055. doi: 10.1097/MD.0000000000001055. Medicine (Baltimore). 2015. PMID: 26131819 Free PMC article.
-
Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.Urology. 2003 Oct;62(4):641-6. doi: 10.1016/s0090-4295(03)00489-8. Urology. 2003. PMID: 14550434 Review.
Cited by
-
Role of Complement in Regulating Inflammation Processes in Renal and Prostate Cancers.Cells. 2021 Sep 15;10(9):2426. doi: 10.3390/cells10092426. Cells. 2021. PMID: 34572075 Free PMC article. Review.
-
Determinants of mortality in patients with type 2 diabetes: a review.Rev Endocr Metab Disord. 2016 Mar;17(1):129-37. doi: 10.1007/s11154-016-9349-0. Rev Endocr Metab Disord. 2016. PMID: 27068710 Review.
-
Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer.Int J Mol Sci. 2023 Jan 4;24(2):910. doi: 10.3390/ijms24020910. Int J Mol Sci. 2023. PMID: 36674430 Free PMC article. Review.
-
An Elevated HbA1c Level Is Associated With Short-Term Adverse Outcomes in Patients With Gastrointestinal Cancer and Type 2 Diabetes Mellitus.J Clin Med Res. 2017 Apr;9(4):303-309. doi: 10.14740/jocmr2607w. Epub 2017 Feb 21. J Clin Med Res. 2017. PMID: 28270890 Free PMC article.
-
Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets.Int J Mol Sci. 2022 Nov 18;23(22):14360. doi: 10.3390/ijms232214360. Int J Mol Sci. 2022. PMID: 36430837 Free PMC article. Review.
References
-
- Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014.
-
- Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer 2009; 16:1103–1123. - PubMed
-
- Coughlin SS, Calle EE, Teras LR, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidem 2004; 159:1160–1167. - PubMed
-
- Magliano DJ, Davis WA, Shaw JE, et al. Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: the Fremantle Diabetes Study. Eur J Endocrinol 2012; 167:589–599. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical